Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality RUO and in vitro diagnostics (IVD) testing. It has more than 50 years’ accumulated experience in the ...

Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality RUO and in vitro diagnostics (IVD) testing. It has more than 50 years' accumulated experience in the ...

Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G sTREM2 Assay for Research Use Only H.U. Group Holdings Inc. and its wholly-owned subsidiary ...

The U.S. Food and Drug Administration cleared the first in vitro diagnostic device that tests blood to aid in diagnosing ...

GENT, Belgium & MALVERN, Pa. & TOKYO — H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the fully automated ...

The FDA has cleared the first-ever blood test for early Alzheimer's detection, which the agency says reduces the need for ...

The Lumipulse test has specifically been approved to help diagnose the disease in the clinical setting. Dr. Amanada Smith said that makes it the first and only test with that advantage.

A simple blood draw has now become a powerful tool in the early fight against Alzheimer’s. The FDA has approved the first ...

The US Food and Drug Administration has given marketing clearance to a blood test to help diagnose Alzheimer’s disease, ...

The USFDA has approved the first-ever blood test to help diagnose Alzheimer's disease, offering a faster, less invasive, and more affordable way to detect early signs ...

A blood sample analysis can detect markers of this disease at early stages, providing a cheaper and less invasive option for diagnosis. In clinical trials, the Lumipulse blood test was highly ...